K-numberK241037
Device nameABL90 FLEX PLUS System
ApplicantRadiometer Medicals Aps
Product codeCEM
Device classClass II
Decision dateJan 14, 2025
DecisionSubstantially Equivalent
Regulation862.1600
AI Summary extracted from FDA summary PDF · never regenerated
Intended use

The ABL90 FLEX PLUS System is a portable, automated blood analyzer that measures electrolytes (potassium, sodium, calcium), glucose, and lactate in heparinized whole blood samples. It is intended for use by trained technologists, nurses, physicians, and therapists in laboratory, point-of-care, or near-patient settings under physician order.

Technological characteristics

The device uses potentiometry for electrolyte measurement and amperometry for glucose and lactate measurement. It features a touch screen, barcode reader, sample mixer, inlet module with two sampling modes (S65 syringe and SP65 short probe), fluid transport system, oximetry module, and optional battery pack. Compared to the ABL90 FLEX predicate, the PLUS version maintains the same operating principles, major components, and consumables (sensor cassette and solution pack), with slightly expanded reportable ranges for calcium (up to 9.94 mg/dL versus 9.92 mg/dL) and glucose (starting at 18 mg/dL versus 9 mg/dL).

Test standards cited

Testing followed Clinical Laboratory Standards Institute (CLSI) guidelines including EP06 (linearity), EP17-A2 (detection capability), EP05-A3 (precision), EP09c (method comparison and bias), EP07 (interference testing), and EP37 (supplemental interference tables). All cited CLSI standards are FDA-recognized consensus standards.

Substantial equivalence argument

The ABL90 FLEX PLUS is substantially equivalent to the ABL90 FLEX predicate because both devices measure the same analytes using identical operating principles (potentiometry and amperometry), target the same intended users and settings, accept the same sample types and volumes with balanced heparin anticoagulant, and share the same major components and consumables. The PLUS model demonstrates acceptable analytical performance across linearity, precision, accuracy (method comparison), and interference testing with results comparable to or better than the predicate. The minor differences in reportable ranges are within acceptable analytical variation and do not affect clinical utility.

Extracted by AI from the official FDA summary PDF →
Source

View the full FDA submission: accessdata.fda.gov

Researching this as a predicate?
Want a transparent AI-ranking score, AI-discovered related predicates, ongoing safety and warning-letter monitoring, full predicate chain lineage, and a drafted SE rationale — all saved to your own project? That's what an account adds.
Start free trial →

Everything you need for a 510(k) submission. Nothing you don't.

14-day free trial. No setup. Cancel anytime.

Start free trial →
Building an AI or ML-enabled device? Predicate search, PCCP tracking, and AI-specific FDA intelligence — built exclusively for AI/ML devices. Try AIFDA Intel →